Key highlights Semaglutide is a glucagon-like peptide-1 receptor agonist that works on GLP-1 receptors in the body to manage blood glucose levels and lose weight by delaying gastric emptying and reducing appetite
Additionally, utilizing a GLP-1 app can streamline your tracking process, making it easier to document your observations and share them with your healthcare team
Combining Treatments: A Synergistic Approach Combining microneedling/exosomes with semaglutide or tirzepatide may offer synergistic benefits
Wei J, Yang B, Wang R, et al
It is to determine if Semaglutide is an appropriate treatment option
Semaglutide was approved for medical use in the US in 2017, and its indications have expanded over the years to include not just type 2 diabetes management but also long-term weight management for adults with obesity or who are overweight and have at least one weight-related comorbidity [20]